Project Scientist at JMI – Jamia Millia Islamia, New Delhi: India

April 13, 2026

Designation/Position- Scientist at JMI

Jamia Millia Islamia, New Delhi, invites applications for Scientist at JMI from eligible and interested candidates.

About- Jamia Millia Islamia is a premier Central University in New Delhi, India. Originally established at Aligarh, United Provinces, during the British Raj in 1920, it moved to its current location in Okhla in 1935. University Grants Commission gave it the deemed status in 1962. Scientist at JMI

Research/Job Area- Biotechnology, Biosciences, or any field of Life Sciences

Location- New Delhi

Eligibility/Qualification–

Minimum Essential Qualifications:

First Class Post Graduate Degree, including the integrated PG degrees OR
Second Class Post Graduate Degree, including the integerated PG degrees with PhD OR
For Engineering/IT/CS- First Class Graduate Degree of Four Years

Desirable: Experienced in applying artificial intelligence in drug design, computing and handling drug descriptor data, and good coding skills in Python/R. Also, the candidate should have hands-on experience in molecular modelling, drug library screening, DFT, WaterMap, MD simulations, or binding free energy computations and analysis.

Upper age limit: 35 years

Job/Position Description-

Project Details:

Project Title: Developing DdpMPyPEPhU as a multitargeted drug for breast cancer using AIguided enumeration-based optimisation, synthesis and preclinical evaluation in PDX model.

Position: Project Research Scientist- I (Non-Medical), Duration: 2 Years Salary: 56,000/- + 30% HRA= 72,800/- pm or as per ICMR guidelines.

Brief Description of the Project

Cancer is a complex and heterogeneous group of diseases characterised by uncontrolled cell proliferation, often leading to metastasis. Our preliminary research has identified DdpMPyPEPhU as a promising anticancer inhibitor for breast cancer (doi: 10.1371/journal.pone.0344028). To accelerate drug discovery and development, we aim to employ advanced in-silico methodologies for comparative reassessment and validation of existing breast cancer drugs alongside our developed candidate, DdpMPyPEPhU. This includes molecular docking, DFT, WaterMap, MD simulations, MMGBSA, and binding affinity predictions. Furthermore, we plan to develop AI-driven drug enumeration techniques to enhance the design and formulation of novel compounds while ensuring optimal physicochemical properties, binding affinity, and stability. These computational approaches aim to streamline drug discovery and optimise lead compounds for clinical translation. Collaborating with our synthetic chemistry team, we will synthesise and characterise DdpMPyPEPhU and its optimised analogues using NMR spectroscopy, mass spectrometry, TLC, and FT-IR. The biochemistry team at AIIMS will subsequently conduct in-vitro validation using multiple breast cancer cell lines, benchmarking the results against standard control drugs. Promising candidates demonstrating significant anticancer activity will undergo in-vivo validation to assess their therapeutic potential.